by Raynovich Rod | Jul 7, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late...
by Raynovich Rod | Jul 21, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit forecast beat. The full year revenue forecast was also cut slightly by...
by Raynovich Rod | Apr 24, 2015 | Biopharmaceuticals
Can Biotech Leadership Continue Up 20% YTD Biotech stocks were roughed up on Friday with a potential market rotation out of healthcare into technology. The XLK Technology SPDR was up 4% for the week compared to only 2% for the IBB. The XLK holds large cap stocks such...